fbpx

News

Lundbeckfonden Ventures News

Cambridge, UK and Indianapolis, US – 5 September 2019: Acacia Pharma Group plc (“Acacia Pharma”, the “Company” or the “Group”), (EURONEXT: ACPH), a pharmaceutical company developing and commercialising hospital products for US and international markets, announces its unaudited interim results for the six-month period ended 30 June 2019. A conference call will take place today at...
Lund, Sweden, 18:00 pm CET, 30 August 2019 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone voids. During August, the number of shares and votes in BONESUPPORT HOLDING AB (publ) has increased due to the exercise of warrants. As of 31 August 2019, the number of shares in BONESUPPORT HOLDING AB...
Lund, Sweden, 10.00 am CET, 21 August 2019 – BONESUPPORT™, listed on Nasdaq Stockholm – an emerging leader in orthobiologics for the management of bone voids, announces that the patient enrollment schedule for the ongoing FORTIFY study is extended. Providing strong clinical evidence in support of its core technology, CERAMENT, is one of the cornerstones...
Cambridge, UK and Indianapolis, US – 16 August 2019: Acacia Pharma Group plc (the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialisation of new nausea and vomiting treatments for surgical and cancer patients, announces that application has been made to Euronext Brussels for the admission of the 106,997 Ordinary Shares of...
Cambridge, UK and Indianapolis, US –  12 August 2019: Acacia Pharma Group plc (“Acacia Pharma”, the “Company”, the “Group”), (EURONEXT: ACPH), a pharmaceutical company developing and commercialising hospital products for US and international markets, will issue its interim results for the six-month period ended 30 June 2019 on Thursday 5 September 2019. A conference call will...
Lund, Sweden, 18:00 CET 31 July 2019 –  During July, the number of shares and votes in BONESUPPORT HOLDING AB (publ) has increased due to the exercise of warrants. As of 31 July 2019, the number of shares in BONESUPPORT HOLDING AB (publ) amounts to 52,351,417 shares, of which 51,846,417 are ordinary shares with one...
Lund, Sweden, 08.00 am CET, 25 July 2019 – BONESUPPORT™, listed on Nasdaq Stockholm – BONESUPPORT HOLDING AB (publ) – listed on Nasdaq Stockholm – an emerging leader in orthobiologics for the management of bone voids, today publish the financial report for thean emerging leader in orthobiologics for the management of bone injuries, today publishes...
Veloxis Pharmaceuticals A/S (OMX: VELO) announced today that it is raising its Outlook for 2019.  This improvement is primarily driven by better than expected uptake of de novo use of Envarsus XR® (tacrolimus extended-release tablets) following the launch of the new indication in January of this year.  In addition to the better than expected de...
Lund, Sweden, 08.00 am CET, 18 July 2019 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone voids will publish its Q2 2019 Interim Report on 25 July 2019 at 08:00 am CET. The Company will hold a conference call and an online presentation on the same day at 13.00 CET. The...
1 3 4 5 6 7 63

Lundbeckfonden Ventures

Nyheder

First patient dosed in pivotal phase 3 trial of SNF472 in calciphylaxis
17. February 2020
Spero Therapeutics Announces Commencement of Rights Offering
11. February 2020
Spero Therapeutics Announces Exercise of $15.9 Million Option by BARDA for Tebipenem HBr Development
5. February 2020